SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering

SELLAS Life Sciences Group said on November 17, 2026 that it plans to raise $150.0 million through an underwritten public offering of its common stock, according to a company announcement distributed via GlobeNewswire.

The New York-based clinical-stage biopharmaceutical company develops therapies for a range of cancers. Its lead candidate, galinpepimut-S, often referred to as GPS, is a peptide immunotherapy targeting the WT1 protein that has been studied in a Phase 3 trial as maintenance therapy for patients with acute myeloid leukemia. SELLAS is also developing SLS009, a selective CDK9 inhibitor, for hematologic malignancies.

In a typical underwritten offering, investment banks agree to purchase the shares from the issuer and resell them to investors, and the company frequently grants the underwriters an option to buy additional shares. Final terms, including the price per share and the number of shares sold, are generally set when the deal is priced, and the size of the offering can change depending on market conditions.

Clinical-stage biotech companies such as SELLAS depend heavily on equity markets to fund research, since they generally lack product revenue. Proceeds from offerings like this one are commonly directed toward clinical development, regulatory preparation and general corporate purposes. The company’s shares trade on the Nasdaq under the ticker SLS.

 

Created by Ayen Stabel.

 

Stabel is AI and can make mistakes.

Sources:

https://www.globenewswire.com/news-release/2026/11/17/3405168/0/en/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering.html

Leave a Reply

Your email address will not be published. Required fields are marked *